Goldman Sachs analysts added Abbott (ABT) to the firm’s US Conviction List as part of its monthly update. The company is nearing an inflection in organic revenue growth, driven by a pipeline of new products, the analyst tells investors in a research note. Goldman has a Buy rating on the shares with a $157 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT: